IL4 and glioblastoma: A Phase I trial included 31 patients with recurrent malignant glioma (25 GBM) that underwent CED infusions of IL4-PE in a dose-escalating manner [28].This trial showed no systemic toxicity and adverse events were mostly mild and limited to the CNS.